# A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)

> **NCT01801163** · PHASE1 · WITHDRAWN · sponsor: **Indiana University**

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib
- **RADIATION:** Stereotactic radiotherapy

## Key facts

- **NCT ID:** NCT01801163
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-02
- **Primary completion:** 2014-08
- **Final completion:** 2014-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial had no patients accrued while open
- **Last updated:** 2015-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01801163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01801163, "A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01801163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*